Spinal Accessory Nerve Stimulation During Neck Dissection (SANE): A Randomised, Single-Blind, Single-Centre External Pilot Study

Research summary

Treatment for head and neck cancer (HNC) often involves chemotherapy and/or radiotherapy followed by surgery, with around 5,000 neck dissections (ND) performed annually in the UK. A major long-term morbidity of ND is “shoulder syndrome,” caused by traction injury to the spinal accessory nerve (SAN). This leads to pain, weakness, and restricted movement, with up to half of patients unable to return to work and one-third continuing to experience dysfunction at 12 months. The socioeconomic impact is expected to grow as HPV-related HNC increasingly affects younger, working-age populations. Current NHS provision lacks a standardised approach to rehabilitation, and physiotherapy offers only modest benefit. There is therefore an unmet need for effective, implementable interventions. Intra-operative electrical nerve stimulation (ES) has been shown to enhance axonal regeneration in animal models and human studies. A Canadian randomised trial demonstrated significant functional improvement with 60 minutes of SAN stimulation, but feasibility was limited by prolonged theatre time and exclusions unrepresentative of UK practice. Emerging evidence indicates that 10 minutes of stimulation may be equally effective while offering a more practical protocol, though this approach has not yet been tested within the NHS. This external pilot trial will evaluate the feasibility of a definitive randomised controlled trial of 10 minutes of intra-operative SAN stimulation versus standard care during ND. Primary objectives are to determine recruitment, retention, outcome completion, and intervention fidelity, as well as to assess operative duration and blinding. A secondary objective is to evaluate the acceptability of the intervention among surgical team members. Additional mechanistic investigations will examine potential biomarkers, including the influence of genetic variation on regenerative responses and perioperative changes in markers of nerve injury. By addressing key feasibility outcomes, this study will establish whether a definitive UK trial is practicable, with potential to inform national strategies for reducing treatment-related morbidity in HNC survivors.

Principal Investigator

Mr Stuart Winter

Contact us

Email: crndirectdelivery team@ouh.nhs.uk

IRAS number

359693